Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
MINNEAPOLIS, April 11, 2023 -- Panbela Therapeutics, Inc. , a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical... | April 11, 2023
United States E Van Cutsem Jennifer Simpson Tammy Groene Drug Administration Cancer Prevention Pharmaceuticals Inc
Source: marketscreener.com